Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hyams

Showing results (291-300 of 366) with videos related to

Pageof 37
Sort By:
Journal of Crohn'S & Colitis|March 17, 2026
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kgElisabeth De Greef, Dan Turner, Jarosław Kierkuś, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2008
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH studyMeena Thayu, Mary B Leonard, Jeffrey S Hyams, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's diseaseRuben J Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Inflammatory Bowel Diseases|December 25, 2008
Long-term outcome of maintenance infliximab therapy in children with Crohn's diseaseJeffrey S Hyams, Trudy Lerer, Anne Griffiths, et al.
Crohn'S & Colitis 360|February 13, 2023
Similar Long-Term Outcomes in Children Presenting With Abscess vs Phlegmon at Diagnosis of Crohn DiseaseAndrew W Fondell, Maua H Mosha, Ross M Maltz, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Journal of Pediatric Gastroenterology and Nutrition|August 26, 2021
Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative ColitisChenthan Krishnakumar, Ashwin N Ananthakrishnan, Brendan M Boyle, et al.
The American Journal of Gastroenterology|January 28, 2010
Outcome following infliximab therapy in children with ulcerative colitisJeffrey S Hyams, Trudy Lerer, Anne Griffiths, et al.
Inflammatory Bowel Diseases|September 7, 2006
Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros, Francisco Sylvester, Subra Kugathasan, et al.
Inflammatory Bowel Diseases|June 23, 2018
Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBDJoseph A Picoraro, Dale Lee, Caren A Heller, et al.
Pageof 37

Showing results (291-300 of 366) with videos related to

Sort By:
Pageof 37
Journal of Crohn'S & Colitis|March 17, 2026
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kgElisabeth De Greef, Dan Turner, Jarosław Kierkuś, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2008
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH studyMeena Thayu, Mary B Leonard, Jeffrey S Hyams, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's diseaseRuben J Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Inflammatory Bowel Diseases|December 25, 2008
Long-term outcome of maintenance infliximab therapy in children with Crohn's diseaseJeffrey S Hyams, Trudy Lerer, Anne Griffiths, et al.
Crohn'S & Colitis 360|February 13, 2023
Similar Long-Term Outcomes in Children Presenting With Abscess vs Phlegmon at Diagnosis of Crohn DiseaseAndrew W Fondell, Maua H Mosha, Ross M Maltz, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Journal of Pediatric Gastroenterology and Nutrition|August 26, 2021
Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative ColitisChenthan Krishnakumar, Ashwin N Ananthakrishnan, Brendan M Boyle, et al.
The American Journal of Gastroenterology|January 28, 2010
Outcome following infliximab therapy in children with ulcerative colitisJeffrey S Hyams, Trudy Lerer, Anne Griffiths, et al.
Inflammatory Bowel Diseases|September 7, 2006
Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros, Francisco Sylvester, Subra Kugathasan, et al.
Inflammatory Bowel Diseases|June 23, 2018
Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBDJoseph A Picoraro, Dale Lee, Caren A Heller, et al.
Pageof 37